Best in 7 days
Pay in installments of $5.91 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jun 13 - Jun 18
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
Zealthy Review: Brand Name Access but Hidden Pricing Vaccine Alliance can you inject tirzepatide cold Where and How to Inject Tirzepatide: Step by Step Guide Compounded' weight loss drugs are a growing problem for state regulators Stateline Weight Loss Injections in Oxford, MS Women's Wellness of Mississippi Noom expands its GLP 1 range with 'microdose' package pharmaphorum
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
Discover Niche Categories That Outsell tirzepatide and grapefruit
Top-Converting Item to Boost Your Average Order
Best in 7 days
Best in 7 days
Best in 7 days
Best in 7 days
4.4 ★★★★★
Based on 1352 reviews
Sort
Product Reviews
★★★★★ 4
Basic knowledge of underwriting is necessary to understand.
Format: Paperback
This is a great guide for underwriting multifamily deals for someone with some basic to moderate knowledge of underwriting. I am a new student to this field and have to stop and google some of the acronyms. For a future version, I think adding an extra page for the acronyms used, definition and equation would be helpful. I think that the font could be larger and darker. Adding mathematical formulas in the book would provide visualization as well. Rob can also provide a sample OM for the reader to use with his underwriting model and compare to his completed one. Again, I am a newbie so my review may change as I gain knowledge in this area. I enjoyed listening to Rob on Youtube/Podcast and hope to learn more from him.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on July 27, 2020
★★★★★ 5
Easy to understand and well organized
Format: Paperback
Author makes complex concepts feel approachable and easy to comprehend. The content is sufficient to be an introductory course
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on October 22, 2025
★★★★★ 5
great read for underwriters of multifamily deals
Format: Kindle
Rob lays out a succinct and thorough summary of his underwriting process, questions industry standards while sharing his opinions, and discusses risk management and analyses for deals during the underwriting process. Highly recommend for newer and more seasoned underwriters and investors to build or sharpen multifamily underwriting fundamentals and details. He also shares his model as the example.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on September 27, 2023
★★★★★ 3
Needs more meat
Format: Paperback
A little on the light side of information provided. Some nuggets. OK value.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on December 16, 2022
★★★★★ 5
Full of useful information
Format: Paperback
As context, I've underwritten about 100 deals and attended some basic underwriting classes. Rob's book was very useful to me, both in helping me gain better skills in underwriting basics (stabilization time period and how unit renovations and rent bumps are modeled/phased-in as well as when to start applying rent escalator) as well as higher level topics, like partnership structures, sensitivity analyses, and judging the returns. In all of these higher level topics I learned several new topics (and calculations to add to my underwriting) and would guess that even experienced investors would pick up a few quality nuggets in these sections.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 27, 2020
